AKAleksey M. Kazakov

Aleksey M. Kazakov

*This is an algorithmically generated author record based on publicly available information.

Aleksey M. Kazakov has a total of 87 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Remote results of treatment of patients with inoperable stage III non-small cell lung cancer (results of the observational study CARL-001)

    by K. K. Laktionov, V. V. Breder, A. K. Allakhverdiev, A. M. Kazakov, A. E. Gorokhov, P. V. Kononets, D. I. Yudin, D. L. Stroyakovskiy, Ya. S. Akhmadiyarova, V. V. Kozlov, et al.

    Introduction. This study examined the treatment outcomes of patients with inoperable stage III non-small cell lung cancer in real-world clinical practice. We determined the frequency and results of molecular genetic testing, and assessed long-term prognoses depending on the chemoradiotherapy regimen and the use of durvalumab maintenance therapy. Aim. To determine the impact of the type of chemoradiotherapy (concurrent or sequential) and the use of durvalumab maintenance therapy after completion of chemoradiotherapy on immediate and long-term treatment outcomes. Materials and methods. The results were obtained during the Lung Cancer Clinical Trial (CARL-001). The study included 166 patients with stage IIIA-IIIC NSCLC. The median age was 63 years. Stage distribution: stage IIIA – 65 patients (39.2%), stage IIIB – 77 (46.4%), and stage IIIC – 24 (14.5%). Patients were also divided by whether they received durvalumab maintenance therapy: 114 patients did not receive durvalumab and 52 did. Results. Molecular genetic analysis data for adenocarcinoma: EGFR status was determined in 39 patients – negative in all patients, not tested in 18 patients. ALK status was determined in 23 patients – negative in all patients, not tested in 34 patients. PD-L1 status (regardless of histotype) – tested in 56 patients, not tested in 110 patients. PD-L1 < 1% – 41 patients (73.3%), 1–49% – 14 patients (25%), 50% or higher –1 patient (1.7%). When comparing the efficacy of concurrent and sequential chemoradiation therapy in the group of patients without maintenance therapy with durvalumab, the following results were obtained: median relapse-free survival (RFS) was 10.0 months versus 12.0 months (sequential vs. concurrent, respectively) and median overall survival (OS) was 36.0 months versus not reached (sequential vs. concurrent, respectively). When comparing the efficacy of chemoimmunotherapy without durvalumab maintenance to chemoimmunotherapy with durvalumab maintenance, the following results were obtained: in the durvalumab group, the median RFS was 20 months, the median OS was not reached, and the objective response rate was 80%. In the group without durvalumab, the median RFS was 11.0 months, the median OS was not reached, and the objective response rate was 89.5%. Conclusions. Concurrent chemoradiotherapy showed a trend toward improved long-term treatment outcomes. Supplementing effective chemoradiotherapy with maintenance durvalumab improves long-term treatment outcomes, including an increase in median relapse-free survival and a trend toward improved overall survival.

  • Open Access

    Predictive value of the KRAS gene mutation variant and co-mutation status when using immunotherapy in patients with non-small cell lung cancer

    by Aleksey M. Kazakov, Marat G. Gordiev, Konstantin K. Laktionov, Svetlana Yu. Kruteleva, Daria D. Tkacheva

    Background. Predicting the disease course and response to various types of drug therapy is an important aspect of treating non-small cell lung cancer (NSCLC). With the rapid development of various molecular genetic testing options, particularly next-generation sequencing, it has become possible to obtain data on a large number of genetic abnormalities simultaneously. This wealth of information on the molecular genetic characteristics of tumors has become available for analysis and subsequent synthesis of data regarding the effectiveness of specific systemic therapies in each individual case, depending on the patient’s mutation status. Aim. To evaluate the impact of KRAS mutations, such as KRAS G12C, G12D, G12V, and G12A, as well as the most common co-mutations with KRAS, on the effectiveness of immunotherapy in the treatment of lung adenocarcinoma. Materials and methods. Collection and analysis of data from foreign and domestic literature on the prognostic significance of the comutation status of patients with KRAS-mutated NSCLC, mainly over the past 5 years. Sources were searched in the PubMed, Cochrane Library, and eLibrary abstract databases. Detailed information on the prognostic significance of the co-mutation status of patients with KRAS-mutated NSCLC is presented. It has been shown that different KRAS mutations, along with various co-mutations, have different impacts on the efficacy of immunotherapy, making expanded genetic testing of NSCLC a relevant and in-demand task with practical application. Conclusion. Determining the co-mutation status of NSCLC patients, particularly the KRAS gene status in combination with other mutations such as TP53, STK11, KEAP1, and others, is crucial for determining sensitivity to immunotherapy and prognosticating the disease course. This field is actively developing both in Russia and internationally, demonstrating its potential and potential practical application.

  • Open Access

    Remote results of treatment of patients of the Russian population with stage I–II non-small cell lung cancer (results of the observational study CARL-001)

    by K. K. Laktionov, V. V. Breder, A. K. Allakhverdiev, A. M. Kazakov, A. E. Gorokhov, P. V. Kononets, D. I. Yudin, D. L. Stroyakovsky, Ya. S. Akhmadiyarova, V. V. Kozlov, et al.

    Introduction. This paper examines the treatment outcomes for patients with stage I and II non-small cell lung cancer (NSCLC) in real clinical practice. The frequency of molecular genetic testing of operated patients was determined, and long-term prognoses for the disease were determined depending on the volume of treatment.Aim. To determine the effect of adding adjuvant treatment to radical surgery on the treatment outcomes in real clinical practice – overall and relapse-free survival. To determine the frequency and results of molecular genetic testing in patients with stage I–II NSCLC.Materials and methods. The results were obtained during the study – clinical approbation of lung cancer (CARL-001). The study included 401 patients with stage I–IIB NSCLC. The study included 129 women and 272 men. The median age was 56 years. There were 272 patients with stage I disease, 129 with stage II. 83 patients received combined treatment, 318 patients received only surgical treatment. The median follow-up was 36 months.Results. PD-L1 testing was performed in 31.7% of patients with stage II and in 14% of patients with stage I. The frequency of testing for mutations in the EGFR and ALK genes was 53.6% and 17.0% for stage II and 46% and 14.8% for stage I, respectively. Three-year overall survival of patients with stage IIA and adjuvant chemotherapy was higher compared to stage IIA patients who did not receive adjuvant treatment – 65% vs 69.24%. A similar indicator in patients with stage IIB also showed an advantage from adjuvant treatment 57.69% vs 72.86% in favor of those who received adjuvant. In patients with stage IIA and adjuvant therapy, 3-year relapse-free survival was 53.86% versus 50.0% without adjuvant. Among patients with stage IIB, the same parameter was 53.85% in the group without adjuvant versus 65.71% in the group that received adjuvant therapy.Conclusions. Adjuvant polychemotherapy in patients with stage II disease has a positive effect on long-term treatment outcomes in the form of increased overall and relapse-free survival compared to patients with a similar stage of the disease without adjuvant treatment. Molecular genetic testing of patients with NSCLC allows us to identify the presence of activating mutations and PD-L1 expression, which is important information for planning further treatment tactics.

  • Open Access

    Experience with perioperative drug therapy in patients with stage III non-small cell lung cancer (results of the observational study CARL-001)

    by K. K. Laktionov, V. V. Breder, A. K. Allahverdiev, A. M. Kazakov, A. E. Gorokhov, D. I. Yudin, D. L. Stroyakovskiy, Ya. S. Akhmadiyarova, V. V. Kozlov, А. М. Федунь, et al.

    Introduction. The article considers approaches to the treatment of patients with stage III non-small-cell lung cancer (NSCLC). Particular attention is paid to neoadjuvant and adjuvant drug therapy.Aim. To evaluate the efficacy of neoadjuvant treatments, such as neoadjuvant chemotherapy and immunochemotherapy, and adjuvant approaches to the stage III NSCLC treatment.Materials and methods. The results were obtained during the study: Clinical Testing of Lung Cancer (“CARL-001”). A total of 186 untreated patients with stage IIIA-IIIC NSCLC (160 patients with stage IIIA, 25 patients with IIIB and 1 with IIIC) were enrolled in the study. The study included 108 patients with adenocarcinoma and 78 with squamous cell carcinoma. 118 patients underwent surgery with adjuvant polychemotherapy (aPCT), 49 patients underwent neoadjuvant polychemotherapy (neoPCT) followed by surgery, and 19 patients had neoadjuvant immunotherapy combined with chemotherapy (neoICT). The median follow-up was 40 months.Results. Both adjuvant and neoadjuvant chemotherapy shared equivalent efficacy. The median relapse-free survival (RFS) in the aPCT and neoPCT groups was 30.4 and 32.6 months, respectively (differences between groups were not statistically significant). There was no significant difference in overall survival (OS) either. The use of neoICT showed better results as compared to neoPCT. The median RFS was not reached in the neoICT group, the median RFS in the neoPCT group was 32.6 months. OS was numerically higher in the neoICT group as compared to the neoPCT group, and accounted for 78.9% and 59.18% over a 36-month follow-up period, respectively.Conclusions. Preoperative chemotherapy is proven to be equal to the postoperative chemotherapy in the treatment of patients with stage III NSCLC. The use of neoICT demonstrated better results as compared to neoPCT. Further study of these treatments will allow a more personalized approach to the treatment of patients with stage III NSCLC.

  • Open Access

    Genomic characteristics of Russian patients with non-small cell lung cancer: Results of next-generation sequencing testing

    by K. K. Laktionov, M. G. Gordiev, K. A. Sarantseva, I. A. Demidova, A. M. Stroganova, M. L. Filipenko, Yu. G. Zhusina, V. V. Karaseva, E. B. Kutirina, A. M. Kazakov, et al.

    Introduction. Next-generation sequencing (NGS) is a molecular approach that can provide clinicians with comprehensive information about a patient’s molecular profile, which is an important aspect of the effective application of targeted therapy.Aim. To assess the frequency of tumor somatic mutations in non-small cell lung cancer (NSCLC) in a cohort of Russian patients to subsequently optimize diagnostics and personalize treatment strategies.Materials and methods. The study included the results of NGS testing from a cohort of 1.400 NSCLC patients between March 17, 2023, and July 22, 2024. Several other clinics across the country participated in this multicenter study. Panels with various options for identifying potential genetic alterations were used. An analysis of the frequency of various alterations was conducted based on the panel used, clinical characteristics of the patients, considering the geographical and ethnographic diversity of the regions in the country.Results. Mutations were most frequently found in the KRAS (17.9%) and EGFR (15.8%) genes, particularly among never-smoker women. The frequency of rare mutations such as RET, MET, and NTRK corresponds to literature data and underscores the need to expand the group of patients being tested for these alterations. However, deletions in exon 19 of EGFR (12.7%) and KRAS G12C (16.4%) were also found among smokers. The results highlight the inadequate scope of existing testing, partly due to the lack of co-mutation assessment and primary resistance mutations, while also demonstrating possible differences when using various diagnostic panels.Conclusion. The implementation of NGS in public health systems allows for a more personalized approach to selecting treatment strategies for patients. The data obtained can be used in predictive models to optimize drug distribution.


  • Open Access

    Use of selpercatinib in a patient with RET-mutated non-small cell lung cancer: case report

    by A. M. Kazakov, K. K. Laktionov, V. O. Vorobyeva, K. A. Sarantseva

    Background. The use of the modern targeted drugs in patients with non-small-cell lung cancer (NSCLC) with certain somatic alterations (genetic alterations in EGFR, ALK, ROS1, BRAF, RET genes, etc.) provides a significant increase in overall and disease-free survival with an acceptable toxicity profile. The use of RET inhibitors, such as selpercatinib, has significantly improved prognosis in NSCLC patients with RET gene translocation, since chemotherapy and immunotherapy in this cohort of patients are ineffective options. The RET gene translocation occurs rarely (2–3 % of cases among lung adenocarcinoma), but detection of this genetic alteration with subsequent administration of targeted therapy significantly improves the prognosis of the disease. Case report. We present a clinical case of the efficacy of targeted therapy with selpercatinib in a 60-year-old patient with RET-positive NSCLC. Methods to eliminate toxicity after selpercatinib therapy and therapy response are described. Results. Second-line selpercatinib therapy resulted in partial response in our patient with lung adenocarcinoma and the presence of translocation in RET gene. Adverse effects from targeted therapy were minimized or eliminated by the use of concomitant therapy, temporary cancellation of targeted therapy with subsequent dose reduction and gradual return to full therapeutic doses. Conclusion. This case demonstrates the high significance and importance of genetic testing in patients with lung adenocarcinoma not only for the most common mutations, but also for rarer somatic alterations, such as translocation in the RET gene. Detection of this translocation and subsequent administration of appropriate targeted therapy significantly improves the prognosis of patients.


  • Open Access

    Genetic profile of patients with stage I–IIIA non-small cell lung cancer

    by A. M. Kazakov, K. K. Laktionov, K. A. Sarantseva

    Background. The article presents data on somatic mutations found in the Russian population of patients with non-small cell lung cancer (NSCLC), their frequency, distribution depending on the histological type of tumor.Aim. To study the molecular genetic profile of Russian patients with stage I–IIIA localized NSCLC, the frequency of occurrence of various somatic mutations, variants of the switching status.Materials and methods. Genetic testing for a panel of 78 genes using the Next Generation Sequencing method of tumor material obtained after surgical treatment of 65 patients with localized stage I–IIIA NSCLC. Processing of the received data was carried out by methods of descriptive statistics.43Results. Mutations in the EGFR, ALK, ROS1, RET, BRAF, KRAS, MET, HER2 genes were found only in adenocarcinoma. Among non-targeted mutations in adenocarcinoma, TP53, STK11, FGFR3, EML4, NF1, RB1, and KMTC2 mutations were the most common. In squamous cell lung cancer, TP53, KMT2C, TSC1, EML4, PTEN, NF1, COL22A1, CDKN2A, RB1, BRCA1 were the most common. Mutations in the EGFR gene were most often associated with mutations in TP53 (30 % of cases), RB1 (15 % of cases), COL22A1 (15 % of cases); ALK was combined with TP53, NF1, WT1 – in 33 % of cases, ROS1 with DDR2 (33 % of cases), ERBB2 was combined with NTRK1, GPC3, HIP1, KIF5B, TP53, XPC, COL22A1 – in 14 % of cases, BRAF was most often associated with mutations in the TP53 gene (14 %) and COL22A1 (13.8 %); a mutation in the RET gene was associated with a TP53 mutation; ROS1 translocation in 50 % of cases was associated with mutations in the TRIM33 and TP53 genes.Conclusion. The data obtained give an idea of the frequency of occurrence of somatic mutations among Russian patients with NSCLC, which is important for the selection of diagnostic panels, interpretation of their results, and also potentially for the development of original custom Next Generation Sequencing testing panels.


  • Open Access

    The use of lean technologies to optimize operating unit of a major Federal center – N. N. Blokhin National Medical Research Center of Oncology of the Ministry of Health of Russia

    by I. S. Stilidi, L. I. Kosova, I. A. Doroshev, V. M. Kulushev, D. A. Ryabchikov, S. A. Artemiev, S. N. Ilyin, A. M. Kazakov, Yu. A. Kolbasuk

    Introduction. Various scientific studies are carried out all over the world aimed at solving issues related to the availability and improvement of the quality of medical care to the population through various measures aimed at improving the integration and coordination of production and technological processes in medical organizations. In our previous works, the key methods for optimizing the operation of the operating unit were outlined, and efficiency was demonstrated with justification for the introduction of methods into the work of not only the operating unit, but also the unit involved in preoperative preparation, but the period for evaluating performance indicators was 1 year. Therefore, the study was continued in the period 2017–2021.The purpose of the study is to evaluate the effectiveness of the practical implementation of the lean technology methodology in the operation of the operational unit.Materials. Statistical data on the results of work of surgical departments of the Research Institute of Clinical Oncology of N. N. Blokhin National Research Medical Center of the Ministry of Health of the Russia for 2017–2021.Results. The expansion of the staff, the active use of all operating rooms, the rational distribution of medical equipment and instruments, the change in the work plan of departments and the routing of surgical patients allowed not only to increase the flow of patients, but also to achieve world standards when planning the operation of the operating unit. Using the example of a progressive increase in the number of operations at the Research Institute of Clinical Oncology from 10 470 in 2017 to 15 140 in 2021, as well as the example of individual surgical departments (surgery departments No. 15, plastic surgery departments), it is possible to trace the process of successful optimization.Conclusion. An example of the development and application of lean technologies in the operating unit of the N. N. Blokhin National Medical Research Center of Oncology of the Ministry of Health of Russia makes it possible to conclude that a competent approach to optimizing the unit is necessary, which can be achieved in a relatively short time by increasing productivity. Lean technologies have helped to significantly reduce the preoperative bedday, significantly increase the productivity of the operating unit, and as a result, increase the number of surgical interventions performed at the center.

  • Open Access

    Mutation in the kras gene as a predictor of the effectiveness of immunotherapy for non-small cell lung cancer

    by K. K. Laktionov, A. M. Kazakov, K. A. Sarantseva, D. S. Scherbo, А. П. Коваль

    The purpose of the study: to conduct a systematic literature review on the effectiveness and feasibility of using information on the presence of KRAS gene mutations (in different codons), TP 53 (KP), ST K11/LKB1 (KL), and KEAP mutations and the association of KRAS m with PD -L1 status in patients with non-small cell lung cancer (NSCLC ) as a predictor of the effectiveness of immunotherapy with immune checkpoint inhibitors.Material and Methods. The review includes data from randomized clinical trials and meta-analyses on the predictive value of KRAS mutation status for response to immunotherapy in patients with NSCLC over the past 10 years.Results. The presence of KRAS mutations in NSCLC patients could be a predictive factor for their response to immunotherapy, as several studies have demonstrated benefit from immunotherapy in these patients. The combination of KRAS mutation with TP 53 (KP) co-mutation predicts a better response to immunotherapy, while a combination with ST K11/LKB1 (KL) and KEAP 1 predicts a worse response (reduced response rate and overall and disease-free survival). In PD -L1-positive patients, the presence of KRAS mutation is associated with a better prognosis after treatment with immunotherapy. Moreover, the presence of KRAS mutation is associated with a worse response to first-line and subsequent-line chemotherapy, thus indicating a more promising use of immunotherapy in these patients.Conclusion. Identification of TP 53 (KP), ST K11/LKB1 (KL), and KEAP 1 co-mutations and the presence of KRAS mutation in addition to determination PD -L expression enable selection of patients who will obtain the greatest benefit from immunotherapy. In addition, the ability to determine KRAS mutation and co-mutation status using a liquid biopsy (with acceptable specificity and sensitivity) makes it possible to use this method for determining sensitivity to immunotherapy when it is not possible to obtain tumor sample (to determine PD 1-L1 expression).